|
Patient survival with immune checkpoint inhibitors and targeted agents in phase 1 trials: A propensity score weighted analysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amcure; Orion |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Mexico) |
Speakers' Bureau - ain You 06/2018 06/2018 Merck Serono; AstraZeneca Spain; Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb; Celgene; GlaxoSmithKline Canada; Gliknik; Janssen; Kura Oncology; Lilly; Merck Sharp & Dome; Novartis; Orion; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca Spain; Merck Serono |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis; Roche |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - GlaxoSmithKline; Puma Biotechnology; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Celldex (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Philips Healthcare (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - GP Pharm; Grunenthal; Novartis; Pierre Fabre; Roche |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech/Roche; Roche; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Roche; SERVIER |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche |
Expert Testimony - Oryzon Genomics |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi |
Speakers' Bureau - Asofarma; Astellas Pharma; Bayer; Johnson & Johnson |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Array BioPharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |
|
|
Consulting or Advisory Role - Astellas Pharma; Novartis; Roche |
Speakers' Bureau - Amgen; Ipsen; MSD Oncology; Roche; Sanofi; Symphogen |
|
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma; Janssen; NeoMed; Roche |
|
Research Funding - Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Glycotope GmbH; Glycotope GmbH; Menarini |